| Trial ID: | L0718 |
| Source ID: | IRCT20121216011763N39
|
| Associated Drug: |
Curcumin
|
| Title: |
Effect of curcumin on lipid profile, blood glucose, anthropometric indices, hepatic function and degree of steatosis, and liver fibrosis measured by fibroscan in non-alcoholic fatty liver patients: a double-blind clinical trial
|
| Acronym: |
--
|
| Status: |
Not Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Non-alcoholic fatty liver. <br>Fatty (change of) liver, not elsewhere classified;K76.0
|
| Interventions: |
Intervention 1: Intervention group: Curcumin, 500 mg oral capsule, once daily for 12 weeks. Intervention 2: Control group: Placebo (lactose) 500 mg orally, once daily for 12 weeks.
|
| Outcome Measures: |
Degree of liver fibrosis. Timepoint: Before intervention, end of intervention. Method of measurement: Fibroscan device.;Degree of liver steatosis. Timepoint: Before intervention, end of intervention. Method of measurement: Fibroscan device.;Alkaline amino transferase. Timepoint: Before intervention, end of intervention. Method of measurement: Enzymatic photometric.;Aspartate amino transferase. Timepoint: Before intervention, end of intervention. Method of measurement: Enzymatic photometric.TG. Timepoint: Before intervention, end of intervention. Method of measurement: Enzymatic.;Tch. Timepoint: Before intervention, end of intervention. Method of measurement: Enzymatic.;HDL. Timepoint: Before intervention, end of intervention. Method of measurement: Enzymatic.;LDL. Timepoint: Before intervention, end of intervention. Method of measurement: Fried Wald Equation equation.;FBS. Timepoint: Before intervention, end of intervention. Method of measurement: Enzymatic.;Weight. Timepoint: Before intervention, end of intervention. Method of measurement: Digital scale.;Waist. Timepoint: Before intervention, end of intervention. Method of measurement: Meters irreversible.;BMI. Timepoint: Before intervention, end of intervention. Method of measurement: Body Mass Index Formula.
|
| Sponsor/Collaborators: |
--
|
| Gender: |
All
|
| Age: |
18 years65 years
|
| Phases: |
Not applicable
|
| Enrollment: |
60
|
| Study Type: |
interventional
|
| Study Designs: |
Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: Randomly, based on the permuted block randomization method, using blocks of 4 that will be blocked based on gender va
|
| Start Date: |
26/11/2019
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
17 December 2019
|
| Locations: |
Iran (Islamic Republic of)
|
| URL: |
http://en.irct.ir/trial/43730
|
